Published in J Med Genet on November 01, 2003
The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br J Cancer (2004) 4.06
American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol (2009) 3.51
Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk. J Natl Cancer Inst (2009) 2.35
Evaluation of the current knowledge limitations in breast cancer research: a gap analysis. Breast Cancer Res (2008) 2.06
Chronic pain reconsidered. Pain (2008) 1.80
High-throughput mammographic-density measurement: a tool for risk prediction of breast cancer. Breast Cancer Res (2012) 1.63
Identification and Management of Women With BRCA Mutations or Hereditary Predisposition for Breast and Ovarian Cancer. Mayo Clin Proc (2010) 1.51
Breast cancer risk prediction and individualised screening based on common genetic variation and breast density measurement. Breast Cancer Res (2012) 1.47
Breast cancer risk assessment across the risk continuum: genetic and nongenetic risk factors contributing to differential model performance. Breast Cancer Res (2012) 1.24
Evaluation of the Tyrer-Cuzick (International Breast Cancer Intervention Study) model for breast cancer risk prediction in women with atypical hyperplasia. J Clin Oncol (2010) 1.16
Prospective validation of the breast cancer risk prediction model BOADICEA and a batch-mode version BOADICEACentre. Br J Cancer (2013) 1.14
Prospective study of Outcomes in Sporadic versus Hereditary breast cancer (POSH): study protocol. BMC Cancer (2007) 1.12
Risk determination and prevention of breast cancer. Breast Cancer Res (2014) 1.11
Breast cancer risk-assessment models. Breast Cancer Res (2007) 1.09
Breast cancer risks and risk prediction models. Breast Care (Basel) (2015) 1.07
Mammographic surveillance in women aged 35-39 at enhanced familial risk of breast cancer (FH02). Fam Cancer (2014) 1.02
Breast Density and Benign Breast Disease: Risk Assessment to Identify Women at High Risk of Breast Cancer. J Clin Oncol (2015) 1.02
Can the breast screening appointment be used to provide risk assessment and prevention advice? Breast Cancer Res (2015) 1.01
Clinical genetic counselling for familial cancers requires reliable data on familial cancer risks and general action plans. J Med Genet (2004) 0.98
Pathogenesis, prevention, diagnosis and treatment of breast cancer. World J Clin Oncol (2014) 0.98
Breast Cancer Risk Prediction Using Clinical Models and 77 Independent Risk-Associated SNPs for Women Aged Under 50 Years: Australian Breast Cancer Family Registry. Cancer Epidemiol Biomarkers Prev (2015) 0.92
Evaluation of the BOADICEA risk assessment model in women with a family history of breast cancer. Fam Cancer (2012) 0.92
Breast cancer risk assessment in 8,824 women attending a family history evaluation and screening programme. Fam Cancer (2014) 0.91
Validation of Rosner-Colditz breast cancer incidence model using an independent data set, the California Teachers Study. Breast Cancer Res Treat (2013) 0.90
The Swedish family-cancer database: update, application to colorectal cancer and clinical relevance. Hered Cancer Clin Pract (2005) 0.90
Acceptance and adherence to chemoprevention among women at increased risk of breast cancer. Breast (2014) 0.90
Validation of the Gail model for predicting individual breast cancer risk in a prospective nationwide study of 28,104 Singapore women. Breast Cancer Res (2012) 0.90
Five-year and lifetime risk of breast cancer among U.S. subpopulations: implications for magnetic resonance imaging screening. Cancer Epidemiol Biomarkers Prev (2010) 0.88
Breast cancer risk assessment in 64,659 women at a single high-volume mammography clinic. Acad Radiol (2011) 0.87
Discriminatory accuracy and potential clinical utility of genomic profiling for breast cancer risk in BRCA-negative women. Breast Cancer Res Treat (2010) 0.86
Applying the 2011 Canadian guidelines for breast cancer screening in practice. CMAJ (2012) 0.85
Implementation in a large health system of a program to identify women at high risk for breast cancer. J Oncol Pract (2011) 0.83
Practical problems with clinical guidelines for breast cancer prevention based on remaining lifetime risk. J Natl Cancer Inst (2015) 0.82
Mammographic density adds accuracy to both the Tyrer-Cuzick and Gail breast cancer risk models in a prospective UK screening cohort. Breast Cancer Res (2015) 0.81
Recalibration of the Gail model for predicting invasive breast cancer risk in Spanish women: a population-based cohort study. Breast Cancer Res Treat (2013) 0.80
Breast cancer risk feedback to women in the UK NHS breast screening population. Br J Cancer (2016) 0.79
Assessing and managing breast cancer risk: clinical tools for advising patients. MedGenMed (2004) 0.78
Breast MRI contrast enhancement kinetics of normal parenchyma correlate with presence of breast cancer. Breast Cancer Res (2016) 0.77
Assessing risk for breast cancer. Breast Cancer Res (2008) 0.77
Probability estimation models for prediction of BRCA1 and BRCA2 mutation carriers: COS compares favourably with other models. Fam Cancer (2007) 0.76
Inequality of use of cancer genetics services by members of breast, ovarian and colorectal cancer families in South East Scotland. Fam Cancer (2008) 0.76
Predicting breast cancer risk: implications of a "weak" family history. Fam Cancer (2008) 0.76
Risk algorithms that include pathology adjustment for HER2 amplification need to make further downward adjustments in likelihood scores. Fam Cancer (2016) 0.75
Relationship of Predicted Risk of Developing Invasive Breast Cancer, as Assessed with Three Models, and Breast Cancer Mortality among Breast Cancer Patients. PLoS One (2016) 0.75
Prospective surveillance of women with a family history of breast cancer: auditing the risk threshold. Br J Cancer (2008) 0.75
SNPs and breast cancer risk prediction for African American and Hispanic women. Breast Cancer Res Treat (2015) 0.75
DCE-MRI Background Parenchymal Enhancement Quantified from an Early versus Delayed Post-contrast Sequence: Association with Breast Cancer Presence. Sci Rep (2017) 0.75
Accounting for individualized competing mortality risks in estimating postmenopausal breast cancer risk. Breast Cancer Res Treat (2016) 0.75
Developing a risk prediction model for breast cancer: a Statistical Utility to Determine Affinity of Neoplasm (SUDAN-CA Breast). Eur J Med Res (2017) 0.75
The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology (1982) 79.76
Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst (1989) 19.87
Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet (1998) 15.09
Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet (1994) 9.60
Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst (1999) 6.60
First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet (2002) 6.02
Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst (2001) 5.97
Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst (1999) 5.92
Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer (1994) 4.37
Regression models in clinical studies: determining relationships between predictors and response. J Natl Cancer Inst (1988) 4.07
Familial breast cancer. BMJ (1994) 2.54
Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2. Lancet (1999) 2.36
Understanding mathematical models for breast cancer risk assessment and counseling. Breast J (2001) 1.54
Limitations of the Gail model in the specialized breast cancer risk assessment clinic. Breast J (2002) 1.11
Comparisons of two breast cancer risk estimates in women with a family history of breast cancer. Cancer Epidemiol Biomarkers Prev (2001) 1.07
Risk assessment and management of high risk familial breast cancer. J Med Genet (2002) 1.01
A comparison of methods currently used in clinical practice to estimate familial breast cancer risks. Ann Oncol (2000) 0.89
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet (2003) 18.67
Plasmid-controlled colonization factor associated with virulence in Esherichia coli enterotoxigenic for humans. Infect Immun (1975) 14.65
Hemagglutination of human group A erythrocytes by enterotoxigenic Escherichia coli isolated from adults with diarrhea: correlation with colonization factor. Infect Immun (1977) 10.84
The state of US health, 1990-2010: burden of diseases, injuries, and risk factors. JAMA (2013) 10.43
Production of vascular permeability factor by enterotoxigenic Escherichia coli isolated from man. Infect Immun (1973) 9.99
New surface-associated heat-labile colonization factor antigen (CFA/II) produced by enterotoxigenic Escherichia coli of serogroups O6 and O8. Infect Immun (1978) 8.52
Differences in the response of rabbit small intestine to heat-labile and heat-stable enterotoxins of Escherichia coli. Infect Immun (1973) 8.47
A strategy to reveal high-frequency RFLPs along the human X chromosome. Am J Hum Genet (1984) 7.73
Stimulation of adenyl cyclase by Escherichia coli enterotoxin. Nat New Biol (1972) 6.65
Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. Ann Intern Med (1992) 6.64
First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet (2002) 6.02
Detection and characterization of colonization factor of enterotoxigenic Escherichia coli isolated from adults with diarrhea. Infect Immun (1978) 5.71
Travelers' diarrhea and toxigenic Escherichia coli. N Engl J Med (1975) 5.20
Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet (2002) 5.06
Campylobacter pylori detected noninvasively by the 13C-urea breath test. Lancet (1987) 5.02
Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell (1999) 5.01
Epidemiology of Helicobacter pylori in an asymptomatic population in the United States. Effect of age, race, and socioeconomic status. Gastroenterology (1991) 4.86
Polymyxin B-Induced Release of Low-Molecular-Weight, Heat-Labile Enterotoxin from Escherichia coli. Infect Immun (1974) 4.79
The initiation sites for RNA transcription in Ad2 DNA. Cell (1977) 4.76
Hemagglutination patterns of enterotoxigenic and enteropathogenic Escherichia coli determined with human, bovine, chicken, and guinea pig erythrocytes in the presence and absence of mannose. Infect Immun (1979) 4.60
Tetrodes markedly improve the reliability and yield of multiple single-unit isolation from multi-unit recordings in cat striate cortex. J Neurosci Methods (1995) 4.60
Three characteristics associated with enterotoxigenic Escherichia coli isolated from man. Infect Immun (1973) 4.42
Attachment of Mycoplasma pneumoniae to respiratory epithelium. Infect Immun (1976) 4.35
Purification and characterization of the CFA/I antigen of enterotoxigenic Escherichia coli. Infect Immun (1979) 4.24
Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res (1997) 4.22
Toxoplasma gondii infection in the United States: seroprevalence and risk factors. Am J Epidemiol (2001) 4.12
Identification of enterotoxigenic Escherichia coli and serum antitoxin activity by the vascular permeability factor assay. Infect Immun (1973) 4.07
The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer (2008) 3.87
Neurocysticercosis in an Orthodox Jewish community in New York City. N Engl J Med (1992) 3.86
Infantile diarrhea produced by heat-stable enterotoxigenic Escherichia coli. N Engl J Med (1976) 3.82
Improved gas chromatographic method for the determination of nicotine and cotinine in biologic fluids. J Chromatogr (1981) 3.72
A sensitive and specific serologic test for detection of Campylobacter pylori infection. Gastroenterology (1989) 3.66
Hypertension treated by salt restriction. Lancet (1978) 3.59
Direct serological assay for the heat-labile enterotoxin of Escherichia coli, using passive immune hemolysis. Infect Immun (1977) 3.57
Trajectory encoding in the hippocampus and entorhinal cortex. Neuron (2000) 3.48
Identification of the familial cylindromatosis tumour-suppressor gene. Nat Genet (2000) 3.42
Diagnostic criteria for schwannomatosis. Neurology (2005) 3.41
Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome. Nat Genet (1992) 3.13
An in vitro method for assessing the plaque forming ability of oral bacteria. Arch Oral Biol (1967) 3.11
A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. J Med Genet (2004) 3.10
Patterns of loss of enterotoxigenicity by Escherichia coli isolated from adults with diarrhea: suggestive evidence for an interrelationship with serotype. Infect Immun (1977) 3.04
Hemagglutination typing of Escherichia coli: definition of seven hemagglutination types. J Clin Microbiol (1980) 3.03
Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology (1992) 3.02
Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol (2006) 2.94
Comparative susceptibility of latin american and united states students to enteric pathogens. N Engl J Med (1976) 2.94
A comparison of the metastatic pattern of infiltrating lobular carcinoma and infiltrating duct carcinoma of the breast. Br J Cancer (1984) 2.89
Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer (2004) 2.87
Hemolysin and K antigens in relation to serotype and hemagglutination type of Escherichia coli isolated from extraintestinal infections. J Clin Microbiol (1981) 2.82
Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics. J Med Genet (2008) 2.81
Differences in serological responses and excretion patterns of volunteers challenged with enterotoxigenic Escherichia coli with and without the colonization factor antigen. Infect Immun (1978) 2.78
Phenocopies in BRCA1 and BRCA2 families: evidence for modifier genes and implications for screening. J Med Genet (2006) 2.68
Role of Escherichia coli colonisation factor antigen in acute diarrhoea. Lancet (1978) 2.65
Seroepidemiology of Helicobacter pylori infection in India. Comparison of developing and developed countries. Dig Dis Sci (1991) 2.63
Oxolinic acid metabolism by man. Arch Int Pharmacodyn Ther (1968) 2.60
The Philadelphia story: the 22q11.2 deletion: report on 250 patients. Genet Couns (1999) 2.58
Oral contraceptives and fatal pulmonary embolism. Lancet (2000) 2.57
Bacterial modulins: a novel class of virulence factors which cause host tissue pathology by inducing cytokine synthesis. Microbiol Rev (1996) 2.55
Familial breast cancer. BMJ (1994) 2.54
Global transcriptional response of Bacillus subtilis to heat shock. J Bacteriol (2001) 2.49
Lemierre's syndrome: more than a historical curiosa. Postgrad Med J (2004) 2.46
Uptake of screening and prevention in women at very high risk of breast cancer. Lancet (2001) 2.45
Virulence factors of enterotoxigenic Escherichia coli. J Infect Dis (1977) 2.45
Bacterially induced bone destruction: mechanisms and misconceptions. Infect Immun (1996) 2.44
Germline E-cadherin gene (CDH1) mutations predispose to familial gastric cancer and colorectal cancer. Hum Mol Genet (1999) 2.41
Location of gene for Gorlin syndrome. Lancet (1992) 2.41
The use of thick-smear antigen slides in the malaria indirect fluorescent antibody test. J Parasitol (1967) 2.40
Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol (1997) 2.39
Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene (2001) 2.36
Oxidative injury and inflammatory periodontal diseases: the challenge of anti-oxidants to free radicals and reactive oxygen species. Crit Rev Oral Biol Med (1999) 2.33
Antimicrobial resistance: Antibiotics and consultant oral microbiologist posts. Br Dent J (2016) 2.32
Perception of risk in women with a family history of breast cancer. Br J Cancer (1993) 2.32
Endoscopic ultrasound guided fine needle aspiration biopsy: a large single centre experience. Gut (1999) 2.28
Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families. Cancer Res (1997) 2.27
The proliferation of normal human breast tissue implanted into athymic nude mice is stimulated by estrogen but not progesterone. Endocrinology (1995) 2.27
Diagnosis of babesiosis: evaluation of a serologic test for the detection of Babesia microti antibody. J Infect Dis (1994) 2.24
An absence of cutaneous neurofibromas associated with a 3-bp inframe deletion in exon 17 of the NF1 gene (c.2970-2972 delAAT): evidence of a clinically significant NF1 genotype-phenotype correlation. Am J Hum Genet (2006) 2.23
Diarrhea caused by Shigella, rotavirus, and Giardia in day-care centers: prospective study. J Pediatr (1981) 2.21
THE RELATION OF THE TUNNICLIFF AND FERRY DIPLOCOCCI TO MEASLES. Am J Public Health (N Y) (1927) 2.19
Validity of the term "family doctor": a limited study in Hamilton, Ontario. Can Med Assoc J (1968) 2.19
Prevention of traveler's diarrhea (emporiatric enteritis). Prophylactic administration of subsalicylate bismuth). JAMA (1980) 2.16
Behaviour of the rod network in the tiger salamander retina mediated by membrane properties of individual rods. J Physiol (1980) 2.15
Li-Fraumeni syndrome--a molecular and clinical review. Br J Cancer (1997) 2.14
Inappropriate hypergastrinaemia in asymptomatic healthy subjects infected with Helicobacter pylori. Gut (1990) 2.13
Mutations, duplication, and deletion of recombined switch regions suggest a role for DNA replication in the immunoglobulin heavy-chain switch. Mol Cell Biol (1989) 2.10
Barbiturate abuse and addiction and their relationship to alcohol and alcoholism. Can Med Assoc J (1971) 2.10
Selected ion monitoring method for determination of nicotine, cotinine and deuterium-labeled analogs: absence of an isotope effect in the clearance of (S)-nicotine-3',3'-d2 in humans. Biol Mass Spectrom (1991) 2.10
Identification of a novel gene cluster encoding staphylococcal exotoxin-like proteins: characterization of the prototypic gene and its protein product, SET1. Infect Immun (2000) 2.07